Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies
Identifieur interne : 003173 ( PascalFrancis/Corpus ); précédent : 003172; suivant : 003174Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies
Auteurs : Andrew W. Roddam ; Naomi E. Allen ; Paul Appleby ; Timothy J. Key ; Luigi Ferrucci ; H. Ballentine Carter ; E. Jeffrey Metter ; CHU CHEN ; Noel S. Weiss ; Annette Fitzpatrick ; Ann W. Hsing ; James V. Jr Lacey ; Kathy Helzlsouer ; Sabina Rinaldi ; Elio Riboli ; Rudolf Kaaks ; Joop A. M. J. L. Janssen ; Mark F. Wildhagen ; Fritz H. Schröder ; Elizabeth A. Platz ; Michael Pollak ; Edward Giovannucci ; Catherine Schaefer ; Charles P. Jr Quesenberry ; Joseph H. Vogelman ; Gianluca Severi ; Dallas R. English ; Graham G. Giles ; P R Stattin ; Göran Hallmans ; Mattias Johansson ; June M. Chan ; Peter Gann ; Steven E. Oliver ; Jeff M. Holly ; Jenny Donovan ; Francois Meyer ; Isabelle Bairati ; Pilar GalanSource :
- Annals of internal medicine [ 0003-4819 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer. Purpose: To assess the association between levels of IGFs and IGFBPs and the subsequent risk for prostate cancer. Data Sources: Studies identified in PubMed, Web of Science, and CancerLit. Study Selection: The principal investigators of all studies that published data on circulating concentrations of sex steroids, IGFs, or IGFBPs and prostate cancer risk using prospectively collected blood samples were invited to collaborate. Data Extraction: Investigators provided individual participant data on circulating concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III and participant characteristics to a central data set in Oxford, United Kingdom. Data Synthesis: The study included data on 3700 men with prostate cancer and 5200 control participants. On average, case patients were 61.5 years of age at blood collection and received a diagnosis of prostate cancer 5 years after blood collection. The greater the serum IGF-I concentration, the greater the subsequent risk for prostate cancer (odds ratio [OR] in the highest vs. lowest quintile, 1.38 [95% Cl, 1.19 to 1.60]; P < 0.001 for trend). Neither IGF-II nor IGFBP-II concentrations were associated with prostate cancer risk, but statistical power was limited. Insulin-like growth factor I and IGFBP-III were correlated (r= 0.58), and although IGFBP-III concentration seemed to be associated with prostate cancer risk, this was secondary to its association with IGF-I levels. Insulin-like growth factor I concentrations seemed to be more positively associated with low-grade than high-grade disease; otherwise, the association between IGFs and IGFBPs and prostate cancer risk had no statistically significant heterogeneity related to stage or grade of disease, time between blood collection and diagnosis, age and year of diagnosis, prostate-specific antigen level at recruitment, body mass index, smoking, or alcohol intake. Limitations: Insulin-like growth factor concentrations were measured in only 1 sample for each participant, and the laboratory methods to measure IGFs differed in each study. Not all patients had disease stage or grade information, and the diagnosis of prostate cancer may differ among the studies. Conclusion: High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 08-0535595 INIST |
|---|---|
| ET : | Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies |
| AU : | RODDAM (Andrew W.); ALLEN (Naomi E.); APPLEBY (Paul); KEY (Timothy J.); FERRUCCI (Luigi); BALLENTINE CARTER (H.); METTER (E. Jeffrey); CHU CHEN; WEISS (Noel S.); FITZPATRICK (Annette); HSING (Ann W.); LACEY (James V. JR); HELZLSOUER (Kathy); RINALDI (Sabina); RIBOLI (Elio); KAAKS (Rudolf); JANSSEN (Joop A. M. J. L.); WILDHAGEN (Mark F.); SCHRÖDER (Fritz H.); PLATZ (Elizabeth A.); POLLAK (Michael); GIOVANNUCCI (Edward); SCHAEFER (Catherine); QUESENBERRY (Charles P. JR); VOGELMAN (Joseph H.); SEVERI (Gianluca); ENGLISH (Dallas R.); GILES (Graham G.); STATTIN (Pär); HALLMANS (Göran); JOHANSSON (Mattias); CHAN (June M.); GANN (Peter); OLIVER (Steven E.); HOLLY (Jeff M.); DONOVAN (Jenny); MEYER (Francois); BAIRATI (Isabelle); GALAN (Pilar) |
| AF : | University of Oxford/Oxford/Royaume-Uni; National Institute on Aging, Harbor Hospital, Johns Hopkins University, and Mercy Medical Center/Baltimore, Maryland/Etats-Unis; Fred Hutchinson Cancer Research Center, Health Sciences, and Collaborative Health Studies Coordinating Center/Seattle, Washington/Etats-Unis; National Cancer Institute/Bethesda, Maryland/Etats-Unis; International Agency for Research on Cancer/Lyon/France; German National Cancer Center/Heidelberg/Allemagne; Imperial College London/London/Royaume-Uni; Erasmus MC/Rotterdam/Pays-Bas; Cancer Prevention Research Unit, Jewish General Hospital-Lady Davis Institute/Montreal/Canada; Centre de Recherche en Cancérologie, Université Laval/Québec/Canada; Harvard School of Public Health/Boston, Massachusetts/Etats-Unis; Kaiser Division of Research/Oakland, California/Etats-Unis; Orentreich Foundation for the Advancement of Science/Cold Spring, New York/Etats-Unis; Cancer Epidemiology Centre, The Cancer Council Victoria/Carlton, Victoria/Australie; Ume? University/Ume?/Suède; University of California, San Francisco/San Francisco, California/Etats-Unis; Northwestern University, Feinberg School of Medicine/Chicago, Illinois/Etats-Unis; University of York, The Hull York Medical School/Heslington, York/Royaume-Uni; University of Bristol, Paul O'Gorman Lifeline Centre, Southmead Hospital/Bristol/Royaume-Uni; UMR SMBH Université/Bobigny/France |
| DT : | Publication en série; Niveau analytique |
| SO : | Annals of internal medicine; ISSN 0003-4819; Coden AIMEAS; Etats-Unis; Da. 2008; Vol. 149; No. 7; Pp. 461-471; Bibl. 40 ref. |
| LA : | Anglais |
| EA : | Background: Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer. Purpose: To assess the association between levels of IGFs and IGFBPs and the subsequent risk for prostate cancer. Data Sources: Studies identified in PubMed, Web of Science, and CancerLit. Study Selection: The principal investigators of all studies that published data on circulating concentrations of sex steroids, IGFs, or IGFBPs and prostate cancer risk using prospectively collected blood samples were invited to collaborate. Data Extraction: Investigators provided individual participant data on circulating concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III and participant characteristics to a central data set in Oxford, United Kingdom. Data Synthesis: The study included data on 3700 men with prostate cancer and 5200 control participants. On average, case patients were 61.5 years of age at blood collection and received a diagnosis of prostate cancer 5 years after blood collection. The greater the serum IGF-I concentration, the greater the subsequent risk for prostate cancer (odds ratio [OR] in the highest vs. lowest quintile, 1.38 [95% Cl, 1.19 to 1.60]; P < 0.001 for trend). Neither IGF-II nor IGFBP-II concentrations were associated with prostate cancer risk, but statistical power was limited. Insulin-like growth factor I and IGFBP-III were correlated (r= 0.58), and although IGFBP-III concentration seemed to be associated with prostate cancer risk, this was secondary to its association with IGF-I levels. Insulin-like growth factor I concentrations seemed to be more positively associated with low-grade than high-grade disease; otherwise, the association between IGFs and IGFBPs and prostate cancer risk had no statistically significant heterogeneity related to stage or grade of disease, time between blood collection and diagnosis, age and year of diagnosis, prostate-specific antigen level at recruitment, body mass index, smoking, or alcohol intake. Limitations: Insulin-like growth factor concentrations were measured in only 1 sample for each participant, and the laboratory methods to measure IGFs differed in each study. Not all patients had disease stage or grade information, and the diagnosis of prostate cancer may differ among the studies. Conclusion: High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer. |
| CC : | 002B01; 002B14D02; 002B20B02 |
| FD : | Cancer de la prostate; Protéine liaison IGFBP; Analyse risque; Donnée médicale; Prospective; Médecine; Homme |
| FG : | Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate |
| ED : | Prostate cancer; Insulin like growth factor binding protein; Risk analysis; Medical data; Prospective; Medicine; Human |
| EG : | Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease |
| SD : | Cáncer de la próstata; Proteína enlace IGFBP; Análisis riesgo; Datos Médicos; Prospectiva; Medicina; Hombre |
| LO : | INIST-2014.354000185689400030 |
| ID : | 08-0535595 |
Links to Exploration step
Pascal:08-0535595Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies</title><author><name sortKey="Roddam, Andrew W" sort="Roddam, Andrew W" uniqKey="Roddam A" first="Andrew W." last="Roddam">Andrew W. Roddam</name><affiliation><inist:fA14 i1="01"><s1>University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>National Institute on Aging, Harbor Hospital, Johns Hopkins University, and Mercy Medical Center</s1><s2>Baltimore, Maryland</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Fred Hutchinson Cancer Research Center, Health Sciences, and Collaborative Health Studies Coordinating Center</s1><s2>Seattle, Washington</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>National Cancer Institute</s1><s2>Bethesda, Maryland</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="05"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>German National Cancer Center</s1><s2>Heidelberg</s2><s3>DEU</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="07"><s1>Imperial College London</s1><s2>London</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="08"><s1>Erasmus MC</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>Cancer Prevention Research Unit, Jewish General Hospital-Lady Davis Institute</s1><s2>Montreal</s2><s3>CAN</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="10"><s1>Centre de Recherche en Cancérologie, Université Laval</s1><s2>Québec</s2><s3>CAN</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="11"><s1>Harvard School of Public Health</s1><s2>Boston, Massachusetts</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="12"><s1>Kaiser Division of Research</s1><s2>Oakland, California</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="13"><s1>Orentreich Foundation for the Advancement of Science</s1><s2>Cold Spring, New York</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="14"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s2>Carlton, Victoria</s2><s3>AUS</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="15"><s1>Ume? University</s1><s2>Ume?</s2><s3>SWE</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="16"><s1>University of California, San Francisco</s1><s2>San Francisco, California</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="17"><s1>Northwestern University, Feinberg School of Medicine</s1><s2>Chicago, Illinois</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="18"><s1>University of York, The Hull York Medical School</s1><s2>Heslington, York</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="19"><s1>University of Bristol, Paul O'Gorman Lifeline Centre, Southmead Hospital</s1><s2>Bristol</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="20"><s1>UMR SMBH Université</s1><s2>Bobigny</s2><s3>FRA</s3></inist:fA14></affiliation></author><author><name sortKey="Allen, Naomi E" sort="Allen, Naomi E" uniqKey="Allen N" first="Naomi E." last="Allen">Naomi E. Allen</name></author><author><name sortKey="Appleby, Paul" sort="Appleby, Paul" uniqKey="Appleby P" first="Paul" last="Appleby">Paul Appleby</name></author><author><name sortKey="Key, Timothy J" sort="Key, Timothy J" uniqKey="Key T" first="Timothy J." last="Key">Timothy J. Key</name></author><author><name sortKey="Ferrucci, Luigi" sort="Ferrucci, Luigi" uniqKey="Ferrucci L" first="Luigi" last="Ferrucci">Luigi Ferrucci</name></author><author><name sortKey="Ballentine Carter, H" sort="Ballentine Carter, H" uniqKey="Ballentine Carter H" first="H." last="Ballentine Carter">H. Ballentine Carter</name></author><author><name sortKey="Metter, E Jeffrey" sort="Metter, E Jeffrey" uniqKey="Metter E" first="E. Jeffrey" last="Metter">E. Jeffrey Metter</name></author><author><name sortKey="Chu Chen" sort="Chu Chen" uniqKey="Chu Chen" last="Chu Chen">CHU CHEN</name></author><author><name sortKey="Weiss, Noel S" sort="Weiss, Noel S" uniqKey="Weiss N" first="Noel S." last="Weiss">Noel S. Weiss</name></author><author><name sortKey="Fitzpatrick, Annette" sort="Fitzpatrick, Annette" uniqKey="Fitzpatrick A" first="Annette" last="Fitzpatrick">Annette Fitzpatrick</name></author><author><name sortKey="Hsing, Ann W" sort="Hsing, Ann W" uniqKey="Hsing A" first="Ann W." last="Hsing">Ann W. Hsing</name></author><author><name sortKey="Lacey, James V Jr" sort="Lacey, James V Jr" uniqKey="Lacey J" first="James V. Jr" last="Lacey">James V. Jr Lacey</name></author><author><name sortKey="Helzlsouer, Kathy" sort="Helzlsouer, Kathy" uniqKey="Helzlsouer K" first="Kathy" last="Helzlsouer">Kathy Helzlsouer</name></author><author><name sortKey="Rinaldi, Sabina" sort="Rinaldi, Sabina" uniqKey="Rinaldi S" first="Sabina" last="Rinaldi">Sabina Rinaldi</name></author><author><name sortKey="Riboli, Elio" sort="Riboli, Elio" uniqKey="Riboli E" first="Elio" last="Riboli">Elio Riboli</name></author><author><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name></author><author><name sortKey="Janssen, Joop A M J L" sort="Janssen, Joop A M J L" uniqKey="Janssen J" first="Joop A. M. J. L." last="Janssen">Joop A. M. J. L. Janssen</name></author><author><name sortKey="Wildhagen, Mark F" sort="Wildhagen, Mark F" uniqKey="Wildhagen M" first="Mark F." last="Wildhagen">Mark F. Wildhagen</name></author><author><name sortKey="Schroder, Fritz H" sort="Schroder, Fritz H" uniqKey="Schroder F" first="Fritz H." last="Schröder">Fritz H. Schröder</name></author><author><name sortKey="Platz, Elizabeth A" sort="Platz, Elizabeth A" uniqKey="Platz E" first="Elizabeth A." last="Platz">Elizabeth A. Platz</name></author><author><name sortKey="Pollak, Michael" sort="Pollak, Michael" uniqKey="Pollak M" first="Michael" last="Pollak">Michael Pollak</name></author><author><name sortKey="Giovannucci, Edward" sort="Giovannucci, Edward" uniqKey="Giovannucci E" first="Edward" last="Giovannucci">Edward Giovannucci</name></author><author><name sortKey="Schaefer, Catherine" sort="Schaefer, Catherine" uniqKey="Schaefer C" first="Catherine" last="Schaefer">Catherine Schaefer</name></author><author><name sortKey="Quesenberry, Charles P Jr" sort="Quesenberry, Charles P Jr" uniqKey="Quesenberry C" first="Charles P. Jr" last="Quesenberry">Charles P. Jr Quesenberry</name></author><author><name sortKey="Vogelman, Joseph H" sort="Vogelman, Joseph H" uniqKey="Vogelman J" first="Joseph H." last="Vogelman">Joseph H. Vogelman</name></author><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name></author><author><name sortKey="English, Dallas R" sort="English, Dallas R" uniqKey="English D" first="Dallas R." last="English">Dallas R. English</name></author><author><name sortKey="Giles, Graham G" sort="Giles, Graham G" uniqKey="Giles G" first="Graham G." last="Giles">Graham G. Giles</name></author><author><name sortKey="Stattin, P R" sort="Stattin, P R" uniqKey="Stattin P" first="P R" last="Stattin">P R Stattin</name></author><author><name sortKey="Hallmans, Goran" sort="Hallmans, Goran" uniqKey="Hallmans G" first="Göran" last="Hallmans">Göran Hallmans</name></author><author><name sortKey="Johansson, Mattias" sort="Johansson, Mattias" uniqKey="Johansson M" first="Mattias" last="Johansson">Mattias Johansson</name></author><author><name sortKey="Chan, June M" sort="Chan, June M" uniqKey="Chan J" first="June M." last="Chan">June M. Chan</name></author><author><name sortKey="Gann, Peter" sort="Gann, Peter" uniqKey="Gann P" first="Peter" last="Gann">Peter Gann</name></author><author><name sortKey="Oliver, Steven E" sort="Oliver, Steven E" uniqKey="Oliver S" first="Steven E." last="Oliver">Steven E. Oliver</name></author><author><name sortKey="Holly, Jeff M" sort="Holly, Jeff M" uniqKey="Holly J" first="Jeff M." last="Holly">Jeff M. Holly</name></author><author><name sortKey="Donovan, Jenny" sort="Donovan, Jenny" uniqKey="Donovan J" first="Jenny" last="Donovan">Jenny Donovan</name></author><author><name sortKey="Meyer, Francois" sort="Meyer, Francois" uniqKey="Meyer F" first="Francois" last="Meyer">Francois Meyer</name></author><author><name sortKey="Bairati, Isabelle" sort="Bairati, Isabelle" uniqKey="Bairati I" first="Isabelle" last="Bairati">Isabelle Bairati</name></author><author><name sortKey="Galan, Pilar" sort="Galan, Pilar" uniqKey="Galan P" first="Pilar" last="Galan">Pilar Galan</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0535595</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0535595 INIST</idno><idno type="RBID">Pascal:08-0535595</idno><idno type="wicri:Area/PascalFrancis/Corpus">003173</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies</title><author><name sortKey="Roddam, Andrew W" sort="Roddam, Andrew W" uniqKey="Roddam A" first="Andrew W." last="Roddam">Andrew W. Roddam</name><affiliation><inist:fA14 i1="01"><s1>University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>National Institute on Aging, Harbor Hospital, Johns Hopkins University, and Mercy Medical Center</s1><s2>Baltimore, Maryland</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Fred Hutchinson Cancer Research Center, Health Sciences, and Collaborative Health Studies Coordinating Center</s1><s2>Seattle, Washington</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="04"><s1>National Cancer Institute</s1><s2>Bethesda, Maryland</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="05"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="06"><s1>German National Cancer Center</s1><s2>Heidelberg</s2><s3>DEU</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="07"><s1>Imperial College London</s1><s2>London</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="08"><s1>Erasmus MC</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="09"><s1>Cancer Prevention Research Unit, Jewish General Hospital-Lady Davis Institute</s1><s2>Montreal</s2><s3>CAN</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="10"><s1>Centre de Recherche en Cancérologie, Université Laval</s1><s2>Québec</s2><s3>CAN</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="11"><s1>Harvard School of Public Health</s1><s2>Boston, Massachusetts</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="12"><s1>Kaiser Division of Research</s1><s2>Oakland, California</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="13"><s1>Orentreich Foundation for the Advancement of Science</s1><s2>Cold Spring, New York</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="14"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s2>Carlton, Victoria</s2><s3>AUS</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="15"><s1>Ume? University</s1><s2>Ume?</s2><s3>SWE</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="16"><s1>University of California, San Francisco</s1><s2>San Francisco, California</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="17"><s1>Northwestern University, Feinberg School of Medicine</s1><s2>Chicago, Illinois</s2><s3>USA</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="18"><s1>University of York, The Hull York Medical School</s1><s2>Heslington, York</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="19"><s1>University of Bristol, Paul O'Gorman Lifeline Centre, Southmead Hospital</s1><s2>Bristol</s2><s3>GBR</s3></inist:fA14></affiliation><affiliation><inist:fA14 i1="20"><s1>UMR SMBH Université</s1><s2>Bobigny</s2><s3>FRA</s3></inist:fA14></affiliation></author><author><name sortKey="Allen, Naomi E" sort="Allen, Naomi E" uniqKey="Allen N" first="Naomi E." last="Allen">Naomi E. Allen</name></author><author><name sortKey="Appleby, Paul" sort="Appleby, Paul" uniqKey="Appleby P" first="Paul" last="Appleby">Paul Appleby</name></author><author><name sortKey="Key, Timothy J" sort="Key, Timothy J" uniqKey="Key T" first="Timothy J." last="Key">Timothy J. Key</name></author><author><name sortKey="Ferrucci, Luigi" sort="Ferrucci, Luigi" uniqKey="Ferrucci L" first="Luigi" last="Ferrucci">Luigi Ferrucci</name></author><author><name sortKey="Ballentine Carter, H" sort="Ballentine Carter, H" uniqKey="Ballentine Carter H" first="H." last="Ballentine Carter">H. Ballentine Carter</name></author><author><name sortKey="Metter, E Jeffrey" sort="Metter, E Jeffrey" uniqKey="Metter E" first="E. Jeffrey" last="Metter">E. Jeffrey Metter</name></author><author><name sortKey="Chu Chen" sort="Chu Chen" uniqKey="Chu Chen" last="Chu Chen">CHU CHEN</name></author><author><name sortKey="Weiss, Noel S" sort="Weiss, Noel S" uniqKey="Weiss N" first="Noel S." last="Weiss">Noel S. Weiss</name></author><author><name sortKey="Fitzpatrick, Annette" sort="Fitzpatrick, Annette" uniqKey="Fitzpatrick A" first="Annette" last="Fitzpatrick">Annette Fitzpatrick</name></author><author><name sortKey="Hsing, Ann W" sort="Hsing, Ann W" uniqKey="Hsing A" first="Ann W." last="Hsing">Ann W. Hsing</name></author><author><name sortKey="Lacey, James V Jr" sort="Lacey, James V Jr" uniqKey="Lacey J" first="James V. Jr" last="Lacey">James V. Jr Lacey</name></author><author><name sortKey="Helzlsouer, Kathy" sort="Helzlsouer, Kathy" uniqKey="Helzlsouer K" first="Kathy" last="Helzlsouer">Kathy Helzlsouer</name></author><author><name sortKey="Rinaldi, Sabina" sort="Rinaldi, Sabina" uniqKey="Rinaldi S" first="Sabina" last="Rinaldi">Sabina Rinaldi</name></author><author><name sortKey="Riboli, Elio" sort="Riboli, Elio" uniqKey="Riboli E" first="Elio" last="Riboli">Elio Riboli</name></author><author><name sortKey="Kaaks, Rudolf" sort="Kaaks, Rudolf" uniqKey="Kaaks R" first="Rudolf" last="Kaaks">Rudolf Kaaks</name></author><author><name sortKey="Janssen, Joop A M J L" sort="Janssen, Joop A M J L" uniqKey="Janssen J" first="Joop A. M. J. L." last="Janssen">Joop A. M. J. L. Janssen</name></author><author><name sortKey="Wildhagen, Mark F" sort="Wildhagen, Mark F" uniqKey="Wildhagen M" first="Mark F." last="Wildhagen">Mark F. Wildhagen</name></author><author><name sortKey="Schroder, Fritz H" sort="Schroder, Fritz H" uniqKey="Schroder F" first="Fritz H." last="Schröder">Fritz H. Schröder</name></author><author><name sortKey="Platz, Elizabeth A" sort="Platz, Elizabeth A" uniqKey="Platz E" first="Elizabeth A." last="Platz">Elizabeth A. Platz</name></author><author><name sortKey="Pollak, Michael" sort="Pollak, Michael" uniqKey="Pollak M" first="Michael" last="Pollak">Michael Pollak</name></author><author><name sortKey="Giovannucci, Edward" sort="Giovannucci, Edward" uniqKey="Giovannucci E" first="Edward" last="Giovannucci">Edward Giovannucci</name></author><author><name sortKey="Schaefer, Catherine" sort="Schaefer, Catherine" uniqKey="Schaefer C" first="Catherine" last="Schaefer">Catherine Schaefer</name></author><author><name sortKey="Quesenberry, Charles P Jr" sort="Quesenberry, Charles P Jr" uniqKey="Quesenberry C" first="Charles P. Jr" last="Quesenberry">Charles P. Jr Quesenberry</name></author><author><name sortKey="Vogelman, Joseph H" sort="Vogelman, Joseph H" uniqKey="Vogelman J" first="Joseph H." last="Vogelman">Joseph H. Vogelman</name></author><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name></author><author><name sortKey="English, Dallas R" sort="English, Dallas R" uniqKey="English D" first="Dallas R." last="English">Dallas R. English</name></author><author><name sortKey="Giles, Graham G" sort="Giles, Graham G" uniqKey="Giles G" first="Graham G." last="Giles">Graham G. Giles</name></author><author><name sortKey="Stattin, P R" sort="Stattin, P R" uniqKey="Stattin P" first="P R" last="Stattin">P R Stattin</name></author><author><name sortKey="Hallmans, Goran" sort="Hallmans, Goran" uniqKey="Hallmans G" first="Göran" last="Hallmans">Göran Hallmans</name></author><author><name sortKey="Johansson, Mattias" sort="Johansson, Mattias" uniqKey="Johansson M" first="Mattias" last="Johansson">Mattias Johansson</name></author><author><name sortKey="Chan, June M" sort="Chan, June M" uniqKey="Chan J" first="June M." last="Chan">June M. Chan</name></author><author><name sortKey="Gann, Peter" sort="Gann, Peter" uniqKey="Gann P" first="Peter" last="Gann">Peter Gann</name></author><author><name sortKey="Oliver, Steven E" sort="Oliver, Steven E" uniqKey="Oliver S" first="Steven E." last="Oliver">Steven E. Oliver</name></author><author><name sortKey="Holly, Jeff M" sort="Holly, Jeff M" uniqKey="Holly J" first="Jeff M." last="Holly">Jeff M. Holly</name></author><author><name sortKey="Donovan, Jenny" sort="Donovan, Jenny" uniqKey="Donovan J" first="Jenny" last="Donovan">Jenny Donovan</name></author><author><name sortKey="Meyer, Francois" sort="Meyer, Francois" uniqKey="Meyer F" first="Francois" last="Meyer">Francois Meyer</name></author><author><name sortKey="Bairati, Isabelle" sort="Bairati, Isabelle" uniqKey="Bairati I" first="Isabelle" last="Bairati">Isabelle Bairati</name></author><author><name sortKey="Galan, Pilar" sort="Galan, Pilar" uniqKey="Galan P" first="Pilar" last="Galan">Pilar Galan</name></author></analytic><series><title level="j" type="main">Annals of internal medicine</title><title level="j" type="abbreviated">Ann. intern. med.</title><idno type="ISSN">0003-4819</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of internal medicine</title><title level="j" type="abbreviated">Ann. intern. med.</title><idno type="ISSN">0003-4819</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term><term>Insulin like growth factor binding protein</term><term>Medical data</term><term>Medicine</term><term>Prospective</term><term>Prostate cancer</term><term>Risk analysis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la prostate</term><term>Protéine liaison IGFBP</term><term>Analyse risque</term><term>Donnée médicale</term><term>Prospective</term><term>Médecine</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer. Purpose: To assess the association between levels of IGFs and IGFBPs and the subsequent risk for prostate cancer. Data Sources: Studies identified in PubMed, Web of Science, and CancerLit. Study Selection: The principal investigators of all studies that published data on circulating concentrations of sex steroids, IGFs, or IGFBPs and prostate cancer risk using prospectively collected blood samples were invited to collaborate. Data Extraction: Investigators provided individual participant data on circulating concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III and participant characteristics to a central data set in Oxford, United Kingdom. Data Synthesis: The study included data on 3700 men with prostate cancer and 5200 control participants. On average, case patients were 61.5 years of age at blood collection and received a diagnosis of prostate cancer 5 years after blood collection. The greater the serum IGF-I concentration, the greater the subsequent risk for prostate cancer (odds ratio [OR] in the highest vs. lowest quintile, 1.38 [95% Cl, 1.19 to 1.60]; P < 0.001 for trend). Neither IGF-II nor IGFBP-II concentrations were associated with prostate cancer risk, but statistical power was limited. Insulin-like growth factor I and IGFBP-III were correlated (r= 0.58), and although IGFBP-III concentration seemed to be associated with prostate cancer risk, this was secondary to its association with IGF-I levels. Insulin-like growth factor I concentrations seemed to be more positively associated with low-grade than high-grade disease; otherwise, the association between IGFs and IGFBPs and prostate cancer risk had no statistically significant heterogeneity related to stage or grade of disease, time between blood collection and diagnosis, age and year of diagnosis, prostate-specific antigen level at recruitment, body mass index, smoking, or alcohol intake. Limitations: Insulin-like growth factor concentrations were measured in only 1 sample for each participant, and the laboratory methods to measure IGFs differed in each study. Not all patients had disease stage or grade information, and the diagnosis of prostate cancer may differ among the studies. Conclusion: High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-4819</s0></fA01><fA02 i1="01"><s0>AIMEAS</s0></fA02><fA03 i2="1"><s0>Ann. intern. med.</s0></fA03><fA05><s2>149</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies</s1></fA08><fA11 i1="01" i2="1"><s1>RODDAM (Andrew W.)</s1></fA11><fA11 i1="02" i2="1"><s1>ALLEN (Naomi E.)</s1></fA11><fA11 i1="03" i2="1"><s1>APPLEBY (Paul)</s1></fA11><fA11 i1="04" i2="1"><s1>KEY (Timothy J.)</s1></fA11><fA11 i1="05" i2="1"><s1>FERRUCCI (Luigi)</s1></fA11><fA11 i1="06" i2="1"><s1>BALLENTINE CARTER (H.)</s1></fA11><fA11 i1="07" i2="1"><s1>METTER (E. Jeffrey)</s1></fA11><fA11 i1="08" i2="1"><s1>CHU CHEN</s1></fA11><fA11 i1="09" i2="1"><s1>WEISS (Noel S.)</s1></fA11><fA11 i1="10" i2="1"><s1>FITZPATRICK (Annette)</s1></fA11><fA11 i1="11" i2="1"><s1>HSING (Ann W.)</s1></fA11><fA11 i1="12" i2="1"><s1>LACEY (James V. JR)</s1></fA11><fA11 i1="13" i2="1"><s1>HELZLSOUER (Kathy)</s1></fA11><fA11 i1="14" i2="1"><s1>RINALDI (Sabina)</s1></fA11><fA11 i1="15" i2="1"><s1>RIBOLI (Elio)</s1></fA11><fA11 i1="16" i2="1"><s1>KAAKS (Rudolf)</s1></fA11><fA11 i1="17" i2="1"><s1>JANSSEN (Joop A. M. J. L.)</s1></fA11><fA11 i1="18" i2="1"><s1>WILDHAGEN (Mark F.)</s1></fA11><fA11 i1="19" i2="1"><s1>SCHRÖDER (Fritz H.)</s1></fA11><fA11 i1="20" i2="1"><s1>PLATZ (Elizabeth A.)</s1></fA11><fA11 i1="21" i2="1"><s1>POLLAK (Michael)</s1></fA11><fA11 i1="22" i2="1"><s1>GIOVANNUCCI (Edward)</s1></fA11><fA11 i1="23" i2="1"><s1>SCHAEFER (Catherine)</s1></fA11><fA11 i1="24" i2="1"><s1>QUESENBERRY (Charles P. JR)</s1></fA11><fA11 i1="25" i2="1"><s1>VOGELMAN (Joseph H.)</s1></fA11><fA11 i1="26" i2="1"><s1>SEVERI (Gianluca)</s1></fA11><fA11 i1="27" i2="1"><s1>ENGLISH (Dallas R.)</s1></fA11><fA11 i1="28" i2="1"><s1>GILES (Graham G.)</s1></fA11><fA11 i1="29" i2="1"><s1>STATTIN (Pär)</s1></fA11><fA11 i1="30" i2="1"><s1>HALLMANS (Göran)</s1></fA11><fA11 i1="31" i2="1"><s1>JOHANSSON (Mattias)</s1></fA11><fA11 i1="32" i2="1"><s1>CHAN (June M.)</s1></fA11><fA11 i1="33" i2="1"><s1>GANN (Peter)</s1></fA11><fA11 i1="34" i2="1"><s1>OLIVER (Steven E.)</s1></fA11><fA11 i1="35" i2="1"><s1>HOLLY (Jeff M.)</s1></fA11><fA11 i1="36" i2="1"><s1>DONOVAN (Jenny)</s1></fA11><fA11 i1="37" i2="1"><s1>MEYER (Francois)</s1></fA11><fA11 i1="38" i2="1"><s1>BAIRATI (Isabelle)</s1></fA11><fA11 i1="39" i2="1"><s1>GALAN (Pilar)</s1></fA11><fA14 i1="01"><s1>University of Oxford</s1><s2>Oxford</s2><s3>GBR</s3></fA14><fA14 i1="02"><s1>National Institute on Aging, Harbor Hospital, Johns Hopkins University, and Mercy Medical Center</s1><s2>Baltimore, Maryland</s2><s3>USA</s3></fA14><fA14 i1="03"><s1>Fred Hutchinson Cancer Research Center, Health Sciences, and Collaborative Health Studies Coordinating Center</s1><s2>Seattle, Washington</s2><s3>USA</s3></fA14><fA14 i1="04"><s1>National Cancer Institute</s1><s2>Bethesda, Maryland</s2><s3>USA</s3></fA14><fA14 i1="05"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3></fA14><fA14 i1="06"><s1>German National Cancer Center</s1><s2>Heidelberg</s2><s3>DEU</s3></fA14><fA14 i1="07"><s1>Imperial College London</s1><s2>London</s2><s3>GBR</s3></fA14><fA14 i1="08"><s1>Erasmus MC</s1><s2>Rotterdam</s2><s3>NLD</s3></fA14><fA14 i1="09"><s1>Cancer Prevention Research Unit, Jewish General Hospital-Lady Davis Institute</s1><s2>Montreal</s2><s3>CAN</s3></fA14><fA14 i1="10"><s1>Centre de Recherche en Cancérologie, Université Laval</s1><s2>Québec</s2><s3>CAN</s3></fA14><fA14 i1="11"><s1>Harvard School of Public Health</s1><s2>Boston, Massachusetts</s2><s3>USA</s3></fA14><fA14 i1="12"><s1>Kaiser Division of Research</s1><s2>Oakland, California</s2><s3>USA</s3></fA14><fA14 i1="13"><s1>Orentreich Foundation for the Advancement of Science</s1><s2>Cold Spring, New York</s2><s3>USA</s3></fA14><fA14 i1="14"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s2>Carlton, Victoria</s2><s3>AUS</s3></fA14><fA14 i1="15"><s1>Ume? University</s1><s2>Ume?</s2><s3>SWE</s3></fA14><fA14 i1="16"><s1>University of California, San Francisco</s1><s2>San Francisco, California</s2><s3>USA</s3></fA14><fA14 i1="17"><s1>Northwestern University, Feinberg School of Medicine</s1><s2>Chicago, Illinois</s2><s3>USA</s3></fA14><fA14 i1="18"><s1>University of York, The Hull York Medical School</s1><s2>Heslington, York</s2><s3>GBR</s3></fA14><fA14 i1="19"><s1>University of Bristol, Paul O'Gorman Lifeline Centre, Southmead Hospital</s1><s2>Bristol</s2><s3>GBR</s3></fA14><fA14 i1="20"><s1>UMR SMBH Université</s1><s2>Bobigny</s2><s3>FRA</s3></fA14><fA20><s1>461-471</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2014</s2><s5>354000185689400030</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>40 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0535595</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of internal medicine</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer. Purpose: To assess the association between levels of IGFs and IGFBPs and the subsequent risk for prostate cancer. Data Sources: Studies identified in PubMed, Web of Science, and CancerLit. Study Selection: The principal investigators of all studies that published data on circulating concentrations of sex steroids, IGFs, or IGFBPs and prostate cancer risk using prospectively collected blood samples were invited to collaborate. Data Extraction: Investigators provided individual participant data on circulating concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III and participant characteristics to a central data set in Oxford, United Kingdom. Data Synthesis: The study included data on 3700 men with prostate cancer and 5200 control participants. On average, case patients were 61.5 years of age at blood collection and received a diagnosis of prostate cancer 5 years after blood collection. The greater the serum IGF-I concentration, the greater the subsequent risk for prostate cancer (odds ratio [OR] in the highest vs. lowest quintile, 1.38 [95% Cl, 1.19 to 1.60]; P < 0.001 for trend). Neither IGF-II nor IGFBP-II concentrations were associated with prostate cancer risk, but statistical power was limited. Insulin-like growth factor I and IGFBP-III were correlated (r= 0.58), and although IGFBP-III concentration seemed to be associated with prostate cancer risk, this was secondary to its association with IGF-I levels. Insulin-like growth factor I concentrations seemed to be more positively associated with low-grade than high-grade disease; otherwise, the association between IGFs and IGFBPs and prostate cancer risk had no statistically significant heterogeneity related to stage or grade of disease, time between blood collection and diagnosis, age and year of diagnosis, prostate-specific antigen level at recruitment, body mass index, smoking, or alcohol intake. Limitations: Insulin-like growth factor concentrations were measured in only 1 sample for each participant, and the laboratory methods to measure IGFs differed in each study. Not all patients had disease stage or grade information, and the diagnosis of prostate cancer may differ among the studies. Conclusion: High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer.</s0></fC01><fC02 i1="01" i2="X"><s0>002B01</s0></fC02><fC02 i1="02" i2="X"><s0>002B14D02</s0></fC02><fC02 i1="03" i2="X"><s0>002B20B02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cancer de la prostate</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Prostate cancer</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Cáncer de la próstata</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Protéine liaison IGFBP</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Insulin like growth factor binding protein</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Proteína enlace IGFBP</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Analyse risque</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Risk analysis</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Análisis riesgo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Donnée médicale</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Medical data</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Datos Médicos</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Prospective</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Prospective</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Prospectiva</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Médecine</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Medicine</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Medicina</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>25</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>25</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>25</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Urinary system disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario patología</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0><s5>40</s5></fC07><fN21><s1>350</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 08-0535595 INIST</NO><ET>Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies</ET><AU>RODDAM (Andrew W.); ALLEN (Naomi E.); APPLEBY (Paul); KEY (Timothy J.); FERRUCCI (Luigi); BALLENTINE CARTER (H.); METTER (E. Jeffrey); CHU CHEN; WEISS (Noel S.); FITZPATRICK (Annette); HSING (Ann W.); LACEY (James V. JR); HELZLSOUER (Kathy); RINALDI (Sabina); RIBOLI (Elio); KAAKS (Rudolf); JANSSEN (Joop A. M. J. L.); WILDHAGEN (Mark F.); SCHRÖDER (Fritz H.); PLATZ (Elizabeth A.); POLLAK (Michael); GIOVANNUCCI (Edward); SCHAEFER (Catherine); QUESENBERRY (Charles P. JR); VOGELMAN (Joseph H.); SEVERI (Gianluca); ENGLISH (Dallas R.); GILES (Graham G.); STATTIN (Pär); HALLMANS (Göran); JOHANSSON (Mattias); CHAN (June M.); GANN (Peter); OLIVER (Steven E.); HOLLY (Jeff M.); DONOVAN (Jenny); MEYER (Francois); BAIRATI (Isabelle); GALAN (Pilar)</AU><AF>University of Oxford/Oxford/Royaume-Uni; National Institute on Aging, Harbor Hospital, Johns Hopkins University, and Mercy Medical Center/Baltimore, Maryland/Etats-Unis; Fred Hutchinson Cancer Research Center, Health Sciences, and Collaborative Health Studies Coordinating Center/Seattle, Washington/Etats-Unis; National Cancer Institute/Bethesda, Maryland/Etats-Unis; International Agency for Research on Cancer/Lyon/France; German National Cancer Center/Heidelberg/Allemagne; Imperial College London/London/Royaume-Uni; Erasmus MC/Rotterdam/Pays-Bas; Cancer Prevention Research Unit, Jewish General Hospital-Lady Davis Institute/Montreal/Canada; Centre de Recherche en Cancérologie, Université Laval/Québec/Canada; Harvard School of Public Health/Boston, Massachusetts/Etats-Unis; Kaiser Division of Research/Oakland, California/Etats-Unis; Orentreich Foundation for the Advancement of Science/Cold Spring, New York/Etats-Unis; Cancer Epidemiology Centre, The Cancer Council Victoria/Carlton, Victoria/Australie; Ume? University/Ume?/Suède; University of California, San Francisco/San Francisco, California/Etats-Unis; Northwestern University, Feinberg School of Medicine/Chicago, Illinois/Etats-Unis; University of York, The Hull York Medical School/Heslington, York/Royaume-Uni; University of Bristol, Paul O'Gorman Lifeline Centre, Southmead Hospital/Bristol/Royaume-Uni; UMR SMBH Université/Bobigny/France</AF><DT>Publication en série; Niveau analytique</DT><SO>Annals of internal medicine; ISSN 0003-4819; Coden AIMEAS; Etats-Unis; Da. 2008; Vol. 149; No. 7; Pp. 461-471; Bibl. 40 ref.</SO><LA>Anglais</LA><EA>Background: Some, but not all, published results have shown an association between circulating blood levels of some insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) and the subsequent risk for prostate cancer. Purpose: To assess the association between levels of IGFs and IGFBPs and the subsequent risk for prostate cancer. Data Sources: Studies identified in PubMed, Web of Science, and CancerLit. Study Selection: The principal investigators of all studies that published data on circulating concentrations of sex steroids, IGFs, or IGFBPs and prostate cancer risk using prospectively collected blood samples were invited to collaborate. Data Extraction: Investigators provided individual participant data on circulating concentrations of IGF-I, IGF-II, IGFBP-II, and IGFBP-III and participant characteristics to a central data set in Oxford, United Kingdom. Data Synthesis: The study included data on 3700 men with prostate cancer and 5200 control participants. On average, case patients were 61.5 years of age at blood collection and received a diagnosis of prostate cancer 5 years after blood collection. The greater the serum IGF-I concentration, the greater the subsequent risk for prostate cancer (odds ratio [OR] in the highest vs. lowest quintile, 1.38 [95% Cl, 1.19 to 1.60]; P < 0.001 for trend). Neither IGF-II nor IGFBP-II concentrations were associated with prostate cancer risk, but statistical power was limited. Insulin-like growth factor I and IGFBP-III were correlated (r= 0.58), and although IGFBP-III concentration seemed to be associated with prostate cancer risk, this was secondary to its association with IGF-I levels. Insulin-like growth factor I concentrations seemed to be more positively associated with low-grade than high-grade disease; otherwise, the association between IGFs and IGFBPs and prostate cancer risk had no statistically significant heterogeneity related to stage or grade of disease, time between blood collection and diagnosis, age and year of diagnosis, prostate-specific antigen level at recruitment, body mass index, smoking, or alcohol intake. Limitations: Insulin-like growth factor concentrations were measured in only 1 sample for each participant, and the laboratory methods to measure IGFs differed in each study. Not all patients had disease stage or grade information, and the diagnosis of prostate cancer may differ among the studies. Conclusion: High circulating IGF-I concentrations are associated with a moderately increased risk for prostate cancer.</EA><CC>002B01; 002B14D02; 002B20B02</CC><FD>Cancer de la prostate; Protéine liaison IGFBP; Analyse risque; Donnée médicale; Prospective; Médecine; Homme</FD><FG>Pathologie de l'appareil génital mâle; Pathologie de l'appareil urinaire; Tumeur maligne; Cancer; Pathologie de la prostate</FG><ED>Prostate cancer; Insulin like growth factor binding protein; Risk analysis; Medical data; Prospective; Medicine; Human</ED><EG>Male genital diseases; Urinary system disease; Malignant tumor; Cancer; Prostate disease</EG><SD>Cáncer de la próstata; Proteína enlace IGFBP; Análisis riesgo; Datos Médicos; Prospectiva; Medicina; Hombre</SD><LO>INIST-2014.354000185689400030</LO><ID>08-0535595</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003173 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003173 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:08-0535595
|texte= Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk : Analysis of Individual Patient Data from 12 Prospective Studies
}}
| This area was generated with Dilib version V0.6.33. |  |